Real Time Touch



new TOP 200 Companies filing patents this week

new Companies with the Most Patent Filings (2010+)




Real Time Touch

Similar
Filing Names

Acorda Therapeutics Inc
Acorda Therapeutics Inc_20131212

Acorda Therapeutics Inc patents


Recent patent applications related to Acorda Therapeutics Inc. Acorda Therapeutics Inc is listed as an Agent/Assignee. Note: Acorda Therapeutics Inc may have other listings under different names/spellings. We're not affiliated with Acorda Therapeutics Inc, we're just tracking patents.

ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 | Company Directory "A" | Acorda Therapeutics Inc-related inventors


Carbonate prodrugs and methods of using the same

The present invention provides carbonate prodrugs which comprise a carbonic phosphoric anhydride prodrug moiety attached to the hydroxyl or carboxyl group of a parent drug moiety. The prodrugs may provide improved physicochemical properties over the parent drug. ... Acorda Therapeutics Inc

Compositions and methods of using chondroitinase abci mutants

One aspect of the present invention relates to mutants of chondroitinase abci. Such chondroitinase abci mutants exhibit altered chondroitin lyase activity or increased resistance to inactivation from stressors including exposure to uv light or heat. ... Acorda Therapeutics Inc

Method for achieving desired glial growth factor 2 plasma levels

The present invention relates to administering glial growth factor 2 (ggf2) to a patient in need thereof, to achieve serum levels of ggf2 within a desired therapeutic window determined based on the disease or disorder afflicting the patient. In a particular embodiment, the patient is suffering from a disease or disorder associated with reduced levels of myelination and the ggf2 is administered to promote myelination in the patient.. ... Acorda Therapeutics Inc

Methods for detecting cardiac damage

The present mention relates to a method for detecting heart damage in a patient. The invention also relates to methods for treatment of patients identified as having heart damage. ... Acorda Therapeutics Inc

Methods for treating an impairment in gait and/or balance in patients with multiple sclerosis using an aminopyridine

Disclosed herein is use of one or more aminopyridines in methods and compositions for treatment of impairments in gait or balance in patients with multiple sclerosis.. . ... Acorda Therapeutics Inc

Chimeric protein

A chimeric protein is disclosed for promoting repair and regeneration of neurons damaged by disease or physical injury wherein the chimeric protein is a combination of a first polypeptide possessing matrix modification activity and a second polypeptide possessing regenerating activity for neural cells.. . ... Acorda Therapeutics Inc

Compositions and methods for extended therapy with aminopyridines

Disclosed herein are methods and compositions related to use of aminopyridines, such as 4-aminopyridine, for use in a therapeutically effective manner for patients with a demyelinating condition, such as multiple sclerosis.. . ... Acorda Therapeutics Inc

Use of 4-aminopyridine to improve neuro-cognitive and/or neuro-psychiatric impairment in patients with demyelinating and other nervous system conditions

Disclosed herein are methods and compositions related to use of aminopyridines, such as 4-aminopyridine, to improve the neuro-cognitive impairments and related neuro-psychiatric impairments of patients with a demyelinating condition such as ms, traumatic brain injury, cerebral palsy, post-radiation encephalopathy.. . ... Acorda Therapeutics Inc

Methods of using sustained release aminopyridine compositions

A pharmaceutical composition which comprises a therapeutically effective amount of a aminopyridine dispersed in a release matrix, including, for example, a composition that can be formulated into a stable, sustained-release oral dosage formulation, such as a tablet which provides, upon administration to a patient, a therapeutically effective plasma level of the aminopyridine for a period of at about 12 hours and the use of the composition to treat various neurological diseases, including multiple sclerosis. A method of selecting individuals based on responsiveness to a treatment, including, for example, identifying individuals who responded to treatment with a sustained release fampridine composition.. ... Acorda Therapeutics Inc

Durable treatment with 4-aminopyridine in patients with demyelination

Disclosed herein are methods and compositions related to the durable use of aminopyridines, such as 4-aminopyridine, to improve impairments of patients with a demyelinating condition, such as ms.. . ... Acorda Therapeutics Inc

Compositions and methods for treatment during non-acute periods following cns neurological injury

This invention relates to treatment of neuroinjury in a post-acute window or in a chronic period following neuroinjury.. . ... Acorda Therapeutics Inc

Methods of using sustained release aminopyridine compositions

A pharmaceutical composition which comprises a therapeutically effective amount of a aminopyridine dispersed in a release matrix, including, for example, a composition that can be formulated into a stable, sustained-release oral dosage formulation, such as a tablet which provides, upon administration to a patient, a therapeutically effective plasma level of the aminopyridine for a period of at about 12 hours and the use of the composition to treat various neurological diseases, including multiple sclerosis. A method of selecting individuals based on responsiveness to a treatment, including, for example, identifying individuals who responded to treatment with a sustained release fampridine composition.. ... Acorda Therapeutics Inc

Sustained release aminopyridine composition

A pharmaceutical composition which comprises a therapeutically effective amount of a aminopyridine dispersed in a release matrix, including, for example, a composition that can be formulated into a stable, sustained-release oral dosage formulation, such as a tablet which provides, upon administration to a patient, a therapeutically effective plasma level of the aminopyridine for a period of at least 12 hours, preferably 24 hours or more and the use of the composition to treat various neurological diseases.. . ... Acorda Therapeutics Inc

Methods for treating an impairment in gait and/or balance in patients with multiple sclerosis using an aminopyridine

Disclosed herein is use of one or more aminopyridines in methods and compositions for treatment of impairments in gait or balance in patients with multiple sclerosis.. . ... Acorda Therapeutics Inc

05/18/17 / #20170137799

Proteoglycan degrading mutants for treatment of cns

The present disclosure relates to the preparation and deletion mutants of chondroitinase proteins and their use in methods for promoting the diffusion of therapeutic composition into tissues and their use for neurological functional recovery after central nervous system (“cns”) injury or disease.. . ... Acorda Therapeutics Inc

03/16/17 / #20170071924

Methods of using sustained release aminopyridine compositions

A pharmaceutical composition which comprises a therapeutically effective amount of a aminopyridine dispersed in a release matrix, including, for example, a composition that can be formulated into a stable, sustained-release oral dosage formulation, such as a tablet which provides, upon administration to a patient, a therapeutically effective plasma level of the aminopyridine for a period of at about 12 hours and the use of the composition to treat various neurological diseases, including multiple sclerosis. A method of selecting individuals based on responsiveness to a treatment, including, for example, identifying individuals who responded to treatment with a sustained release fampridine composition.. ... Acorda Therapeutics Inc

03/02/17 / #20170056385

Use of 4-aminopyridine to improve neuro-cognitive and/or neuro-psychiatric impairment in patients with demyelinating and other nervous system conditions

Disclosed herein are methods and compositions related to use of aminopyridines, such as 4-aminopyridine, to prove the neuro-cognitive impairments and related neuro-psychiatric impairments of patients with a demyelinating condition such as ms, traumatic brain injury, cerebral palsy, post-radiation encephalopathy.. . ... Acorda Therapeutics Inc

02/09/17 / #20170035742

Durable treatment with 4-aminopyridine in patients with demyelination

Disclosed herein are methods and compositions related to the durable use of aminopyridines, such as 4-aminopyridine, to improve impairments of patients with a demyelinating condition, such as ms.. . ... Acorda Therapeutics Inc

02/02/17 / #20170028038

Compositions and methods of using chondroitinase abci mutants

The present disclosure relates to protein and nucleic acid mutants of chondroitinase abci. Such nucleic acid mutants encode for chondroitinase abci mutant enzymes exhibiting altered chondroitin lyase activity or increased resistance to inactivation from stressors including uv light or heat. ... Acorda Therapeutics Inc

01/12/17 / #20170009222

Compositions and methods of using chondroitinase abci mutants

One aspect of the present invention relates to mutants of chondroitinase abci. Such chondroitinase abci mutants exhibit altered chondroitin lyase activity or increased resistance to inactivation from stressors including exposure to uv light or heat. ... Acorda Therapeutics Inc

01/12/17 / #20170008916

Carbonate prodrugs and methods of using the same

The present invention provides carbonate prodrugs which comprise a carbonic phosphoric anhydride prodrug moiety attached to the hydroxyl or carboxyl group of a parent drug moiety. The prodrugs may provide improved physicochemical properties over the parent drug. ... Acorda Therapeutics Inc








ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009



###

This listing is an abstract for educational and research purposes is only meant as a recent sample of applications filed, not a comprehensive history. Freshpatents.com is not affiliated or associated with Acorda Therapeutics Inc in any way and there may be associated servicemarks. This data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Acorda Therapeutics Inc with additional patents listed. Browse our Agent directory for other possible listings. Page by FreshPatents.com

###